|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
Crescendo Bioscience's Vectra™ DA Test Indicates Remission in Rheumatoid Arthritis Patients
6/6/2012 11:44:17 AM
BERLIN--(BUSINESS WIRE)--Crescendo Bioscience®, Inc., a molecular diagnostics company developing quantitative biomarker tests for rheumatoid arthritis (RA) and other inflammatory diseases, today announced data indicating that the Company’s multi-biomarker blood test, Vectra™ DA, may help identify patients in remission based on measuring 12 protein biomarkers that indicate the overall level of RA disease activity. Patients in remission according to the Vectra DA algorithm showed a lower observed risk of radiographic progression over the next year than those in remission according to other clinical remission criteria examined in a study. Moreover, a high Vectra DA algorithm was associated with an increased risk of joint damage progression during the next year, even in patients classified as being in remission by clinical assessment. Additional data show the use of Vectra DA can help inform treatment decisions and influence RA patient care. These, and other data, are being presented at the European League Against Rheumatism’s (EULAR) Annual European Congress of Rheumatology in Berlin, June 6-9, 2012.
|
|
|
|
|
|
|
|
|
|
|